Progress in Acute Myeloid Leukemia
Copyright policy )Progress in Acute Myeloid Leukemia
Significant progress has been made in the treatment of acute myeloid leukemia (AML). Steady gains in clinical research and a renaissance of genomics in leukemia have led to improved outcomes. The recognition of tremendous heterogeneity in AML has allowed individualized treatments of specific disease entities within the context of patient age, cytogenetics, and mutational analysis. The following is a comprehensive review of the current state of AML therapy and a roadmap of our approach to these distinct disease entities.
- University of California, San Francisco United States
- The University of Texas MD Anderson Cancer Center United States
Myeloid, Homologous, Pediatric Research Initiative, Pediatric Cancer, Childhood Leukemia, Oncology and Carcinogenesis, Clinical Sciences, Abnormal Karyotype, Review, Acute, Cardiovascular medicine and haematology, Targeted therapy, Rare Diseases, AML, Clinical Research, Antineoplastic Combined Chemotherapy Protocols, Humans, Transplantation, Homologous, Cancer, Pediatric, Chromosome Aberrations, Transplantation, Leukemia, Vascular Endothelial Growth Factor Receptor-1, Biomedical and Clinical Sciences, Age Factors, Hematopoietic Stem Cell Transplantation, Nuclear Proteins, Oncology and carcinogenesis, Hematology, Leukemia, Myeloid, Acute, Good Health and Well Being, Treatment Outcome, Mutation, Nucleophosmin
Myeloid, Homologous, Pediatric Research Initiative, Pediatric Cancer, Childhood Leukemia, Oncology and Carcinogenesis, Clinical Sciences, Abnormal Karyotype, Review, Acute, Cardiovascular medicine and haematology, Targeted therapy, Rare Diseases, AML, Clinical Research, Antineoplastic Combined Chemotherapy Protocols, Humans, Transplantation, Homologous, Cancer, Pediatric, Chromosome Aberrations, Transplantation, Leukemia, Vascular Endothelial Growth Factor Receptor-1, Biomedical and Clinical Sciences, Age Factors, Hematopoietic Stem Cell Transplantation, Nuclear Proteins, Oncology and carcinogenesis, Hematology, Leukemia, Myeloid, Acute, Good Health and Well Being, Treatment Outcome, Mutation, Nucleophosmin
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).43 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!